{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:28:41Z","timestamp":1790630921687,"version":"4.1.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T00:00:00Z","timestamp":1653955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T00:00:00Z","timestamp":1653955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01KG2104"],"award-info":[{"award-number":["01KG2104"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01KG2104"],"award-info":[{"award-number":["01KG2104"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01KG2104"],"award-info":[{"award-number":["01KG2104"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01KG2104"],"award-info":[{"award-number":["01KG2104"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01KG2104"],"award-info":[{"award-number":["01KG2104"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01KG2104"],"award-info":[{"award-number":["01KG2104"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01KG2104"],"award-info":[{"award-number":["01KG2104"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70113307"],"award-info":[{"award-number":["70113307"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The efficacy of SARS-CoV-2 vaccination in patients with hematological malignancies (HM) appears limited due to disease and treatment-associated immune impairment. We conducted a systematic review of prospective studies published from 10\/12\/2021 onwards in medical databases to assess clinical efficacy parameters, humoral and cellular immunogenicity and adverse events (AE) following two doses of COVID-19 approved vaccines. In 57 eligible studies reporting 7393 patients, clinical outcomes were rarely reported and rates of SARS-CoV-2 infection (range 0\u201311.9%), symptomatic disease (0\u20132.7%), hospital admission (0\u20132.8%), or death (0\u20130.5%) were low. Seroconversion rates ranged from 38.1\u201399.1% across studies with the highest response rate in myeloproliferative diseases and the lowest in patients with chronic lymphocytic leukemia. Patients with B-cell depleting treatment had lower seroconversion rates as compared to other targeted treatments or chemotherapy. The vaccine-induced T-cell response was rarely and heterogeneously reported (26.5\u201385.9%). Similarly, AEs were rarely reported (0\u201350.9% \u22651 AE, 0\u20137.5% \u22651 serious AE). In conclusion, HM patients present impaired humoral and cellular immune response to COVID-19 vaccination with disease and treatment specific response patterns. In light of the ongoing pandemic with the easing of mitigation strategies, new approaches to avert severe infection are urgently needed for this vulnerable patient population that responds poorly to current COVID-19 vaccine regimens.<\/jats:p>","DOI":"10.1038\/s41408-022-00684-8","type":"journal-article","created":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T07:05:44Z","timestamp":1653980744000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review"],"prefix":"10.1038","volume":"12","author":[{"given":"Vanessa","family":"Piechotta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3928-2503","authenticated-orcid":false,"given":"Sibylle C.","family":"Mellinghoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2011-1010","authenticated-orcid":false,"given":"Caroline","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Brinkmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Iannizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8922-0488","authenticated-orcid":false,"given":"Nina","family":"Kreuzberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3286-1131","authenticated-orcid":false,"given":"Anne","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Monsef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jannik","family":"Stemler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9599-3137","authenticated-orcid":false,"given":"Oliver A.","family":"Cornely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9662-9900","authenticated-orcid":false,"given":"Paul J.","family":"Br\u00f6ckelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4744-6192","authenticated-orcid":false,"given":"Nicole","family":"Skoetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,31]]},"reference":[{"key":"684_CR1","unstructured":"World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard: World Health Organisation. 2020b. https:\/\/covid19.who.int\/. Accessed 14 March 2022."},{"key":"684_CR2","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41416-021-01396-9","volume":"125","author":"AF Bertuzzi","year":"2021","unstructured":"Bertuzzi AF, Ciccarelli M, Marrari A, Gennaro N, Dipasquale A, Giordano L, et al. Impact of active cancer on COVID-19 survival: a matched-analysis on 557 consecutive patients at an Academic Hospital in Lombardy, Italy. Br J Cancer. 2021;125:358\u201365.","journal-title":"Br J Cancer"},{"key":"684_CR3","doi-asserted-by":"crossref","unstructured":"ElGohary GM, Hashmi S, Styczynski J, Kharfan-Dabaja MA, Alblooshi RM, de la C\u00e1mara R, et al. The risk and prognosis of COVID-19 infection in cancer patients: a systematic review and meta-analysis. Hematol Oncol Stem Cell Ther. 2020.","DOI":"10.1016\/j.hemonc.2020.07.005"},{"key":"684_CR4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40164-020-00177-z","volume":"9","author":"JL Pi\u00f1ana","year":"2020","unstructured":"Pi\u00f1ana JL, Martino R, Garc\u00eda-Garc\u00eda I, Parody R, Morales MD, Benzo G, et al. Risk factors and outcome of COVID-19 in patients with hematological malignancies. Exp Hematol Oncol. 2020;9:21.","journal-title":"Exp Hematol Oncol"},{"key":"684_CR5","unstructured":"Pagano L, Salmanton-Garc\u00eda J, Marchesi F, Busca A, Corradini P, Hoenigl M, et al. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). J Hematol Oncol [Internet]. 2021. http:\/\/europepmc.org\/abstract\/MED\/34649563."},{"key":"684_CR6","unstructured":"Ontario Agency for Health Protection and Promotion. COVID-19 real-world vaccine effectiveness\u2014what we know so far. Toronto: Queen\u2019s Printer for Ontario; 2021."},{"key":"684_CR7","doi-asserted-by":"publisher","first-page":"ofab353","DOI":"10.1093\/ofid\/ofab353","volume":"8","author":"ME Agha","year":"2021","unstructured":"Agha ME, Blake M, Chilleo C, Wells A, Haidar G. Suboptimal response to Coronavirus disease 2019 messenger RNA vaccines in patients with hematologic malignancies: a need for vigilance in the postmasking era. Open Forum Infect Dis. 2021;8:ofab353. https:\/\/doi.org\/10.1093\/ofid\/ofab353.","journal-title":"Open Forum Infect Dis"},{"key":"684_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00530-3","volume":"11","author":"E Terpos","year":"2021","unstructured":"Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I, Briasoulis A, Gumeni S, Malandrakis P, et al. The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. Blood Cancer J. 2021;11:138-.","journal-title":"Blood Cancer J"},{"key":"684_CR9","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMoa2108891","volume":"385","author":"J Lopez Bernal","year":"2021","unstructured":"Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med. 2021;385:585\u201394.","journal-title":"N Engl J Med"},{"key":"684_CR10","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41586-021-03777-9","volume":"596","author":"D Planas","year":"2021","unstructured":"Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021;596:276\u201380.","journal-title":"Nature."},{"key":"684_CR11","doi-asserted-by":"publisher","first-page":"S1161","DOI":"10.1016\/j.annonc.2021.08.1639","volume":"32","author":"R Passalacqua","year":"2021","unstructured":"Passalacqua R, Ratti M, Pan A, Testa S, Molteni A, Tonoli S, et al. Efficacy of SARS-CoV-2 vaccination in cancer patients during treatment: A prospective observational study (ANTICOV trial). Ann Oncol. 2021;32:S1161\u2013S.","journal-title":"Ann Oncol"},{"key":"684_CR12","doi-asserted-by":"publisher","unstructured":"Koch TA-O, Mellinghoff SC, Shamsrizi PA-O, Addo MA-O, Dahlke CA-O. Correlates of vaccine-induced protection against SARS-CoV-2. LID. https:\/\/doi.org\/10.3390\/vaccines9030238.","DOI":"10.3390\/vaccines9030238"},{"key":"684_CR13","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00262-005-0015-8","volume":"55","author":"F Ravandi","year":"2006","unstructured":"Ravandi F, O\u2019Brien S. Immune defects in patients with chronic lymphocytic leukemia. Cancer Immunol Immunother. 2006;55:197\u2013209.","journal-title":"Cancer Immunol Immunother"},{"key":"684_CR14","first-page":"CD008983","volume":"2","author":"R Bitterman","year":"2018","unstructured":"Bitterman R, Eliakim-Raz N, Vinograd I, Zalmanovici Trestioreanu A, Leibovici L, Paul M. Influenza vaccines in immunosuppressed adults with cancer. Cochr Database Syst Rev. 2018;2:CD008983.","journal-title":"Cochr Database Syst Rev"},{"key":"684_CR15","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1182\/blood-2012-06-438689","volume":"120","author":"D Bedognetti","year":"2012","unstructured":"Bedognetti D, Ansaldi F, Zanardi E, Durando P, Sertoli MR, Massucco C, et al. Seasonal and pandemic (A\/H1N1 2009) MF-59\u2013adjuvanted influenza vaccines in complete remission non-Hodgkin lymphoma patients previously treated with rituximab containing regimens. Blood. 2012;120:1954\u20137.","journal-title":"Blood"},{"key":"684_CR16","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1158\/2643-3230.BCD-22-0013","volume":"3","author":"SM Rubinstein","year":"2022","unstructured":"Rubinstein SM, Bhutani D, Lynch RC, Hsu C-Y, Shyr Y, Advani S, et al. Patients recently treated for B-lymphoid malignancies show increased risk of severe COVID-19. Blood Cancer Discov. 2022;3:181\u201393.","journal-title":"Blood Cancer Discov"},{"key":"684_CR17","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.ccell.2021.06.009","volume":"39","author":"A Addeo","year":"2021","unstructured":"Addeo A, Shah PK, Bordry N, Hudson RD, Albracht B, Di Marco M, et al. Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. Cancer Cell. 2021;39:1091\u20138.","journal-title":"Cancer Cell"},{"key":"684_CR18","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.ccell.2021.07.012","volume":"39","author":"LM Greenberger","year":"2021","unstructured":"Greenberger LM, Saltzman LA, Senefeld JW, Johnson PW, DeGennaro LJ, Nichols GL. Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies. Cancer Cell. 2021;39:1031\u20133.","journal-title":"Cancer Cell"},{"key":"684_CR19","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41408-021-00534-z","volume":"11","author":"FA-O Malard","year":"2021","unstructured":"Malard FA-O, Gaugler B, Gozlan J, Bouquet L, Fofana D, Siblany L, et al. Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies. Blood Cancer J. 2021;11:142.","journal-title":"Blood Cancer J"},{"key":"684_CR20","doi-asserted-by":"publisher","first-page":"e583","DOI":"10.1016\/S2352-3026(21)00169-1","volume":"8","author":"K Maneikis","year":"2021","unstructured":"Maneikis K, \u0160ablauskas K, Ringelevii\u010di\u016bt\u0117 U, Vaitek\u0117nait\u0117 V, \u010cekauskien\u0117 R, Kry\u017eauskait\u0117 L, et al. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. Lancet Haematol. 2021;8:e583\u201392.","journal-title":"Lancet Haematol"},{"key":"684_CR21","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S1470-2045(21)00213-8","volume":"22","author":"L Monin","year":"2021","unstructured":"Monin L, Laing AG, Mu\u00f1oz-Ruiz M, McKenzie DR, Del Molino Del Barrio I, Alaguthurai T. et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 2021;22:765\u201378.","journal-title":"Lancet Oncol"},{"key":"684_CR22","unstructured":"McGill COVID19 Vaccine Tracker Team. COVID-19 vaccine tracker. 2021. https:\/\/covid19.trackvaccines.org\/vaccines\/."},{"key":"684_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev. 2016;5:210.","journal-title":"Syst Rev"},{"key":"684_CR24","doi-asserted-by":"crossref","unstructured":"Guyatt G, Oxman Ad Fau, Akl EA, Akl Ea Fau, Kunz R, Kunz R, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383\u201394.","DOI":"10.1016\/j.jclinepi.2010.04.026"},{"key":"684_CR25","doi-asserted-by":"publisher","first-page":"h870","DOI":"10.1136\/bmj.h870","volume":"350","author":"A Iorio","year":"2015","unstructured":"Iorio A, Spencer FA, Falavigna M, Alba C, Lang E, Burnand B, et al. Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients. BMJ. 2015;350:h870.","journal-title":"BMJ"},{"key":"684_CR26","doi-asserted-by":"publisher","first-page":"103705","DOI":"10.1016\/j.ebiom.2021.103705","volume":"74","author":"B Peter","year":"2021","unstructured":"Peter B, Ola B, Lotta H, Stephan M, Piotr N, Puran C, et al. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. EBioMedicine. 2021;74:103705.","journal-title":"EBioMedicine"},{"key":"684_CR27","doi-asserted-by":"publisher","first-page":"174.","DOI":"10.1186\/s13045-021-01190-3","volume":"14","author":"L Canti","year":"2021","unstructured":"Canti L, Humblet-Baron S, Desombere I, Neumann J, Pannus P, Heyndrickx L, et al. Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients. J Hematol Oncol. 2021;14:174.","journal-title":"J Hematol Oncol"},{"key":"684_CR28","doi-asserted-by":"publisher","first-page":"6273","DOI":"10.1158\/0008-5472.CAN-21-3554","volume":"81","author":"J Figueiredo","year":"2021","unstructured":"Figueiredo J, Merin NM, Hamid O, Choi SY, Lemos T, Cozen W, et al. Longitudinal SARS-CoV-2 mRNA vaccine-induced humoral immune responses in cancer patients. Cancer Res. 2021;81:6273\u201380.","journal-title":"Cancer Res"},{"key":"684_CR29","doi-asserted-by":"publisher","first-page":"ciab930","DOI":"10.1093\/cid\/ciab930","volume":"30","author":"AC Sherman","year":"2021","unstructured":"Sherman AC, Desjardins M, Cheng CA, Bausk B, Izaguirre N, Zhou G, et al. SARS-CoV-2 mRNA vaccines in allogeneic hematopoietic stem cell transplant recipients: immunogenicity and reactogenicity. Clin Infect Dis. 2021;30:ciab930.","journal-title":"Clin Infect Dis"},{"key":"684_CR30","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1038\/s41375-021-01354-7","volume":"35","author":"SD Stampfer","year":"2021","unstructured":"Stampfer SD, Goldwater MS, Jew S, Bujarski S, Regidor B, Daniely D, et al. Response to mRNA vaccination for COVID-19 among patients with multiple myeloma. Leukemia. 2021;35:3534\u201341.","journal-title":"Leukemia"},{"key":"684_CR31","doi-asserted-by":"publisher","first-page":"303.e1","DOI":"10.1016\/j.cmi.2021.10.007","volume":"28","author":"M Yeshurun","year":"2022","unstructured":"Yeshurun M, Pasvolsky O, Shargian L, Yahav D, Ben-Zvi H, Rubinstein M, et al. Humoral serologic response to the BNT162b2 vaccine after allogeneic haematopoietic cell transplantation. Clin Microbiol Infect. 2022;28:303.e1\u2013303.e4.","journal-title":"Clin Microbiol Infect"},{"key":"684_CR32","doi-asserted-by":"publisher","first-page":"e547","DOI":"10.1097\/HS9.0000000000000547","volume":"5","author":"M Gavriatopoulou","year":"2021","unstructured":"Gavriatopoulou M, Ntanasis-Stathopoulos I, Korompoki E, Terpos E, Dimopoulos MA. SARS-CoV-2 vaccines in patients with multiple myeloma. Hemasphere. 2021;5:e547.","journal-title":"Hemasphere"},{"key":"684_CR33","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41409-021-01487-4","volume":"57","author":"M Salvini","year":"2022","unstructured":"Salvini M, Maggi F, Damonte C, Mortara L, Bruno A, Mora B, et al. Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation. Bone Marrow Transplant. 2022;57:137\u20139.","journal-title":"Bone Marrow Transplant"},{"key":"684_CR34","doi-asserted-by":"publisher","first-page":"100274.","DOI":"10.1016\/j.esmoop.2021.100274","volume":"6","author":"M Peeters","year":"2021","unstructured":"Peeters M, Verbruggen L, Teuwen L, Vanhoutte G, Vande Kerckhove S, Peeters B, et al. Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment. ESMO Open. 2021;6:100274.","journal-title":"ESMO Open"},{"key":"684_CR35","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1182\/blood.2021013714","volume":"139","author":"H Soledad","year":"2022","unstructured":"Soledad H, Jeremie Z, Timothee B, Amani O, Delphine P, Paul D, et al. Anti-CD38 therapy impairs SARS-CoV-2 vaccine response in multiple myeloma patients. Blood. 2022;139:942\u20136.","journal-title":"Blood"},{"key":"684_CR36","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.ccell.2021.09.001","volume":"39","author":"LM Greenberger","year":"2021","unstructured":"Greenberger LM, Saltzman LA, Senefeld JW, Johnson PW, DeGennaro LJ, Nichols GL. Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies. Cancer Cell. 2021;39:1297\u20139.","journal-title":"Cancer Cell"},{"key":"684_CR37","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41408-021-00579-0","volume":"11","author":"D Cattaneo","year":"2021","unstructured":"Cattaneo D, Bucelli C, Cavallaro F, Consonni D, Iurlo A. Impact of diagnosis and treatment on response to COVID-19 vaccine in patients with BCR-ABL1-negative myeloproliferative neoplasms. A single-center experience. Blood Cancer J. 2021;11:185","journal-title":"Blood Cancer J"},{"key":"684_CR38","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.ccell.2021.08.001","volume":"39","author":"M Mairhofer","year":"2021","unstructured":"Mairhofer M, Kausche L, Kaltenbrunner S, Ghanem R, Stegemann M, Klein K. et al. Humoral and cellular immune responses in SARS-CoV-2 mRNA-vaccinated patients with cancer. Cancer Cell. 2021;39:1171\u20132.","journal-title":"Cancer Cell"},{"key":"684_CR39","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1158\/2643-3230.BCD-21-0142","volume":"2","author":"R Tamari","year":"2021","unstructured":"Tamari R, Politikos I, Knorr DA, Vardhana SA, Young JC, Marcello LT, et al. Predictors of humoral response to SARS-CoV-2 vaccination after hematopoietic cell transplantation and CAR T-cell therapy. Blood Cancer Discov. 2021;2:577\u201385.","journal-title":"Blood Cancer Discov"},{"key":"684_CR40","first-page":"e21","volume":"196","author":"WY Chan","year":"2022","unstructured":"Chan WY, Howells L, Wilson W, Sanchez E, Ainley L, Chavda SJ, et al. Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV-19 COVID-19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease factors. Br J Haematol. 2022;196:e21\u20136.","journal-title":"Br J Haematol"},{"key":"684_CR41","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.jtct.2021.06.024","volume":"27","author":"R Ram","year":"2021","unstructured":"Ram R, Hagin D, Kikozashvilli N, Freund T, Amit O, Bar-On Y, et al. Safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients after allogeneic HCT or CD19-based CART therapy\u2014a single-center prospective cohort study. Transpl Cell Ther. 2021;27:788\u201394.","journal-title":"Transpl Cell Ther"},{"key":"684_CR42","doi-asserted-by":"crossref","unstructured":"Lindemann M, Klisanin V, Th\u00fcmmler L, Fisenkci N, Tsachakis-M\u00fcck N, Ditschkowski M, et al. Humoral and Cellular Vaccination Responses against SARS-CoV-2 in Hematopoietic Stem Cell Transplant Recipients. Vaccines. 2021;9:1075.","DOI":"10.3390\/vaccines9101075"},{"key":"684_CR43","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1016\/j.ccell.2021.09.015","volume":"39","author":"A Aleman","year":"2021","unstructured":"Aleman A, Upadhyaya B, Tuballes K, Kappes K, Gleason CR, Beach K, et al. Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma. Cancer Cell. 2021;39:1442\u20134.","journal-title":"Cancer Cell"},{"key":"684_CR44","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/j.ccell.2021.10.003","volume":"39","author":"DR McKenzie","year":"2021","unstructured":"McKenzie DR, Mu\u00f1oz-Ruiz M, Monin L, Alaguthurai T, Lechmere T, Abdul-Jawad S, et al. Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer. Cancer Cell. 2021;39:1445\u20137.","journal-title":"Cancer Cell"},{"key":"684_CR45","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/bjh.18066","volume":"197","author":"R Karthik","year":"2022","unstructured":"Karthik R, Ross S, Sally J, Paul W, Sherin V, Alison T, et al. Immune response to COVID-19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T cell response. Br J Haematol. 2022;197:293\u2013301.","journal-title":"Br J Haematol"},{"key":"684_CR46","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.ccell.2021.07.016","volume":"39","author":"S Ehmsen","year":"2021","unstructured":"Ehmsen S, Asmussen A, Jeppesen SS, Nilsson AC, \u00d8sterlev S, Vestergaard H, et al. Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer. Cancer Cell. 2021;39:1034\u20136.","journal-title":"Cancer Cell"},{"key":"684_CR47","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/s43018-021-00274-w","volume":"2","author":"A Fendler","year":"2021","unstructured":"Fendler A, Shepherd STC, Au L, Wilkinson KA, Wu M, Byrne F, et al. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. Nat Cancer. 2021;2:1305\u201320.","journal-title":"Nat Cancer"},{"key":"684_CR48","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/bjh.17877","volume":"196","author":"V Marasco","year":"2022","unstructured":"Marasco V, Carniti C, Guidetti A, Farina L, Magni M, Miceli R, et al. T-cell immune response after mRNA SARS-CoV-2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies. Br J Haematol. 2022;196:548\u201358.","journal-title":"Br J Haematol"},{"key":"684_CR49","doi-asserted-by":"crossref","unstructured":"Cattaneo C, Cancelli V, Pagani C, Ogna A, Tucci A, Rossi G, et al. Impaired humoral response in lymphoma patients surviving the acute phase of COVID-19. Hematol Oncol. 2021;39(Suppl 2).","DOI":"10.1002\/hon.196_2880"},{"key":"684_CR50","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/ajh.26385","volume":"97","author":"JL Pi\u00f1ana","year":"2022","unstructured":"Pi\u00f1ana JL, L\u00f3pez-Corral L, Martino R, Montoro J, Vazquez L, P\u00e9rez A, et al. Infectious Complications Subcommittee of the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH-TC). SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group. Am J Hematol. 2022;97:30\u201342.","journal-title":"Am J Hematol"},{"key":"684_CR51","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1016\/S0264-410X(00)00409-6","volume":"19","author":"A Hartkamp","year":"2001","unstructured":"Hartkamp A, Mulder AH, Rijkers GT, van Velzen-Blad H, Biesma DH. Antibody responses to pneumococcal and haemophilus vaccinations in patients with B-cell chronic lymphocytic leukaemia. Vaccine. 2001;19:1671\u20137.","journal-title":"Vaccine."},{"key":"684_CR52","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.vaccine.2021.01.001","volume":"39","author":"JA Whitaker","year":"2021","unstructured":"Whitaker JA, Parikh SA, Shanafelt TD, Kay NE, Kennedy RB, Grill DE, et al. The humoral immune response to high-dose influenza vaccine in persons with monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL). Vaccine. 2021;39:1122\u201330.","journal-title":"Vaccine."},{"key":"684_CR53","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/s41375-020-0884-z","volume":"35","author":"FR Mauro","year":"2021","unstructured":"Mauro FR, Giannarelli D, Galluzzo CM, Vitale C, Visentin A, Riemma C, et al. Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL). Leukemia. 2021;35:737\u201346.","journal-title":"Leukemia."},{"key":"684_CR54","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.1016\/j.vaccine.2018.05.012","volume":"36","author":"T Svensson","year":"2018","unstructured":"Svensson T, K\u00e4ttstr\u00f6m M, Hammarlund Y, Roth D, Andersson PO, Svensson M, et al. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group. Vaccine. 2018;36:3701\u20137.","journal-title":"Vaccine."},{"key":"684_CR55","doi-asserted-by":"publisher","first-page":"e114966","DOI":"10.1371\/journal.pone.0114966","volume":"9","author":"M Pasiarski","year":"2014","unstructured":"Pasiarski M, Rolinski J, Grywalska E, Stelmach-Goldys A, Korona-Glowniak I, Gozdz S, et al. Antibody and plasmablast response to 13-valent pneumococcal conjugate vaccine in chronic lymphocytic leukemia patients\u2013preliminary report. PLoS ONE. 2014;9:e114966.","journal-title":"PLoS ONE"},{"key":"684_CR56","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/s41591-021-01386-7","volume":"27","author":"EM Bange","year":"2021","unstructured":"Bange EM, Han NA, Wileyto P, Kim JY, Gouma S, Robinson J, et al. CD8\u2009+\u2009T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nat Med. 2021;27:1280\u20139.","journal-title":"Nat Med"},{"key":"684_CR57","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1038\/s41591-021-01507-2","volume":"27","author":"SA Apostolidis","year":"2021","unstructured":"Apostolidis SA, Kakara M, Painter MM, Goel RR, Mathew D, Lenzi K, et al. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med. 2021;27:1990\u20132001.","journal-title":"Nat Med"},{"key":"684_CR58","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1158\/2643-3230.BCD-21-0222","volume":"3","author":"TA-O Shree","year":"2022","unstructured":"Shree TA-O, Shankar V, Lohmeyer JA-O, Czerwinski DK, Schroers-Martin JA-O, Rodriguez GM, et al. CD20-targeted therapy ablates de novo antibody response to vaccination but spares preestablished immunity. Blood Cancer Discov. 2022;3:95\u2013102.","journal-title":"Blood Cancer Discov"},{"key":"684_CR59","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3324\/haematol.2019.238634","volume":"106","author":"JM Logue","year":"2021","unstructured":"Logue JM, Zucchetti E, Bachmeier CA, Krivenko GS, Larson V, Ninh D, et al. Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. Haematologica. 2021;106:978\u201386.","journal-title":"Haematologica"},{"key":"684_CR60","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1038\/s41591-021-01507-2","volume":"27","author":"SA Apostolidis","year":"2021","unstructured":"Apostolidis SA, Kakara M, Painter MM, Goel RR, Mathew D, Lenzi K, et al. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med. 2021;27:1990\u20132001.","journal-title":"Nat Med."},{"key":"684_CR61","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","volume":"385","author":"SJ Thomas","year":"2021","unstructured":"Thomas SJ, Moreira ED, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. N Engl J Med. 2021;385:1761\u201373.","journal-title":"N Engl J Med"},{"key":"684_CR62","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","volume":"385","author":"N Barda","year":"2021","unstructured":"Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, et al. Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med. 2021;385:1078\u201390.","journal-title":"N Engl J Med"},{"key":"684_CR63","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1001\/jama.2021.15072","volume":"326","author":"NP Klein","year":"2021","unstructured":"Klein NP, Lewis N, Goddard K, Fireman B, Zerbo O, Hanson KE, et al. Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA. 2021;326:1390\u20139.","journal-title":"JAMA"},{"key":"684_CR64","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S0140-6736(22)00152-0","volume":"399","author":"DR Feikin","year":"2022","unstructured":"Feikin DR, Higdon MM, Abu-Raddad LJ, Andrews N, Araos R, Goldberg Y, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022;399:924\u201344.","journal-title":"Lancet"},{"key":"684_CR65","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.ccell.2022.02.010","volume":"40","author":"MB Abid","year":"2022","unstructured":"Abid MB, Rubin M, Ledeboer N, Szabo A, Longo W, Mohan M, et al. Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients. Cancer Cell. 2022;40:340\u20132.","journal-title":"Cancer Cell"},{"key":"684_CR66","first-page":"41","volume":"7","author":"J Koch","year":"2022","unstructured":"Koch J, Vygen-Bonnet S, Bogdan C, Burchard G, Garbe E, Heininger U, et al. STIKO-Empfehlung zur 2. COVID-19-Auffrischimpfung mit einem mRNAImpfstoff f\u00fcr besonders gesundheitlich gef\u00e4hrdete bzw. exponierte Personengruppen und die dazugeh\u00f6rige wissenschaftliche Begr\u00fcndung. Epid Bull. 2022;7:41\u201357.","journal-title":"Epid Bull"},{"key":"684_CR67","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1016\/S2213-2600(22)00010-8","volume":"10","author":"TK Burki","year":"2022","unstructured":"Burki TK. Fourth dose of COVID-19 vaccines in Israel. Lancet Respir Med. 2022;10:e19.","journal-title":"Lancet Respir Med"},{"key":"684_CR68","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/S0140-6736(22)00147-7","volume":"399","author":"A Fendler","year":"2022","unstructured":"Fendler A, Shepherd STC, Au L, Wu M, Harvey R, Schmitt AM, et al. Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer. Lancet. 2022;399:905\u20137.","journal-title":"Lancet"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00684-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00684-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00684-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T20:09:00Z","timestamp":1669234140000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00684-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,31]]},"references-count":68,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["684"],"URL":"https:\/\/doi.org\/10.1038\/s41408-022-00684-8","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,31]]},"assertion":[{"value":"31 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"VP, AB, CH, CI, AA, IM, NK, JS, PJB, and NS declare no financial conflicts of interest with regard to the present study. SCM reports grants from DZIF. OAC reports grants or contracts from Amplyx, Basilea, BMBF, Cidara, DZIF, EU-DG RTD (101037867), F2G, Gilead, Matinas, MedPace, MSD, Mundipharma, Octapharma, Pfizer, Scynexis; Consulting fees from Amplyx, Biocon, Biosys, Cidara, Da Volterra, Gilead, Matinas, MedPace, Menarini, Molecular Partners, MSG-ERC, Noxxon, Octapharma, PSI, Scynexis, Seres; Honoraria for lectures from Abbott, Al-Jazeera Pharmaceuticals, Astellas, Grupo Biotoscana\/United Medical\/Knight, Hikma, MedScape, MedUpdate, Merck\/MSD, Mylan, Pfizer; Payment for expert testimony from Cidara; Participation on a Data Safety Monitoring Board or Advisory Board from Actelion, Allecra, Cidara, Entasis, IQVIA, Jannsen, MedPace, Paratek, PSI, Shionogi; A patent at the German Patent and Trade Mark Office (DE 10 2021 113 007.7); Other interests from DGHO, DGI, ECMM, ISHAM, MSG-ERC, Wiley.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"86"}}